Sign up
Pharma Capital

Vyome Therapeutics expects data from its anti-biotic resistant acne drug end of 2019

Vyome Therapeutics Inc CEO Venkat Nelabhotla sat down with Proactive Investors at the BIO CEO & Investor Conference in New York.

Vyome Therapeutics is a clinical stage speciality pharmaceutical company, with platform technologies and a pipeline of drugs for antibiotic-resistant acne and other skin pathogens.

 

View full VYOME profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.